Loading clinical trials...
Loading clinical trials...
Diagnostic Efficacy of 18F-FAPI-74 PET/CT in Patients With Colon Cancer
Whole body CT is the primary imaging method in staging and follow-up of colon cancer. Conventional PET-CT with 18F-labeled fluorodeoxyglucose (18F-FDG) has its limitations and has a secondary role in colon cancer protocols. A new PET tracer, fibroblast activation protein inhibitor (FAPI), targeting a protein that is overexpressed by cancer-associated fibroblasts presents a potential new PET imaging tool. The objective of this prospective study is to evaluate diagnostic efficacy of 18F-FAPI-74 PET/CT in patients with colon cancer. The aim is to evaluate the sensitivity and specificity of 18F-FAPI-74 in detection of local lymph node metastasis and distant metastasis in patient level in patients with colon cancer in primary staging and when suspected recurrence. 100 patients with colon cancer are enrolled and PET/CT studies are performed with the novel 18F-FAPI-74 tracer. The data will be collected between 2024-2026.
Age
18 - 85 years
Sex
ALL
Healthy Volunteers
No
Turku PET Centre, Turku University Hospital
Turku, Finland
Start Date
October 9, 2024
Primary Completion Date
October 1, 2026
Completion Date
October 1, 2026
Last Updated
December 9, 2025
100
ESTIMATED participants
PET/CT ([F-18]FAPI-74)
DEVICE
Lead Sponsor
Turku University Hospital
NCT04704661
NCT04674267
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions